Article
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.
Blood cancer journal - 20 Mar 2015
Rustad E H, Dai H Y, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda L A, Sandvik A K, Wader K F, Misund K, Sundan A, Aarset H, Waage A
Abstract excerpt
In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF V600E by allele-specific real-time PCR (AS-PCR). Positive results were confirmed by immunohistochemistry, Sanger sequencing and, in three patients from whom we had stored purified myeloma cells,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.